Valisure’s CEO, David Light, was invited to participate in the workshop titled, Understanding How the Public Perceives and Values Pharmaceutical Quality, presented by Robert J. Margolis, MD, Center for Health Policy at Duke University, in partnership with the FD on February 3, 2020. The day provided an opportunity to explore and better understand how stakeholders perceive and value the quality of pharmaceutical products.
David joined key FDA leadership, and staff provided comments on the Agency’s current thinking, and attendees were able to ask questions and engage with panelists. Topics for discussion included:
Valisure’s CEO, David Light, was invited to participate in the workshop titled, Understanding How the Public Perceives and Values Pharmaceutical Quality, presented by Robert J. Margolis, MD, Center for Health Policy at Duke University, in partnership with the FD on February 3, 2020. The day provided an opportunity to explore and better understand how stakeholders perceive and value the quality of pharmaceutical products.
David joined key FDA leadership, and staff provided comments on the Agency’s current thinking, and attendees were able to ask questions and engage with panelists. Topics for discussion included:
Valisure’s CEO, David Light, was invited to participate in the workshop titled, Understanding How the Public Perceives and Values Pharmaceutical Quality, presented by Robert J. Margolis, MD, Center for Health Policy at Duke University, in partnership with the FD on February 3, 2020. The day provided an opportunity to explore and better understand how stakeholders perceive and value the quality of pharmaceutical products.
David joined key FDA leadership, and staff provided comments on the Agency’s current thinking, and attendees were able to ask questions and engage with panelists. Topics for discussion included:
Valisure’s CEO, David Light, was invited to participate in the workshop titled, Understanding How the Public Perceives and Values Pharmaceutical Quality, presented by Robert J. Margolis, MD, Center for Health Policy at Duke University, in partnership with the FD on February 3, 2020. The day provided an opportunity to explore and better understand how stakeholders perceive and value the quality of pharmaceutical products.
David joined key FDA leadership, and staff provided comments on the Agency’s current thinking, and attendees were able to ask questions and engage with panelists. Topics for discussion included: